[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"North American Rescue LLC.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":119},{"warningLetters":4,"total":118},[5,31,53,74,97],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2127,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-04-18T13:20:00Z\">04\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-12-27T05:00:00Z\">12\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-diagnostics-llc-643203-12272022\">North American Diagnostics, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Elizabeth A. Lashinsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Diagnostics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>618 Ridgewood Ave., Suite 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Holly Hill\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32117\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ealash52@gmail.com\"> ealash52@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 643203\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDecember 27, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Lashinsky:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, North American Diagnostics, LLC (“North American,” “you,” or “your firm”), located at 618 Ridgewood Ave, Suite 100, Holly Hill, Florida on five dates from June 14 through 23, 2022. During this inspection, FDA investigators determined that your firm is a manufacturer and distributor of SARS-CoV-2 antigen rapid test kits under the names ORAL RAPID SARS-CoV-2 Antigen Rapid test kits, SDI LABS SARS-CoV-2 Antigen Rapid Test Kit, North American Diagnostics SARS-CoV-2 Antigen Rapid Test Kit, Skippack Medical Labs SARS-CoV-2 Antigen Rapid Test (Colloidal Gold), and Spectrum DX Lab SARS-CoV-2 Antigen Rapid test kits (hereafter referred to as “COVID-19 Test”). Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your COVID-19 test has been distributed in the United States (U.S.). without marketing approval, clearance, or authorization from FDA. Indeed, in your response dated July 6, 2022, concerning our investigators’ observations noted on the Form FDA 483 List of Inspectional Observations, that was issued to your firm, you acknowledged that you had “improperly distributed into commerce” COVID-19 test kits. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “\u003Cstrong>Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)\u003C\u002Fstrong>” provides FDA’s review priorities and enforcement policies regarding novel coronavirus (COVID-19) tests.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that your COVID-19 test is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a).\u003C\u002Fstrong> Specifically, your firm did not establish design control procedures prior to the manufacture and distribution of your COVID-19 test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to develop, conduct, control, and monitor production processes to ensure the device conforms to its specifications, as required by 21 CDR 820.70.\u003C\u002Fstrong> Specifically, your firm has not established production processes controls for your COVID-19 test, for any production and process changes, environmental control requirements, personnel requirements, contamination control requirements, manufacturing material requirements, or automated processes requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a).\u003C\u002Fstrong> Specifically, your firm has not conducted process validations for those processes that your firm cannot fully verify in the manufacture of your COVID-19 Test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80.\u003C\u002Fstrong> Specifically, your firm has not established 1) receiving acceptance activities for any components used to manufacture your COVID-19 Test, 2) in-process acceptance activities for any process critical to the functionality and\u002For intended use of the device, 3) final acceptance activities.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fstrong> Specifically, your firm has not established procedures, instructions, or processes to identify, investigate, and correct problems that are observed and to prevent recurrence of issues.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR 820.160(a).\u003C\u002Fstrong> Specifically, your firm does not have procedures for control and distribution of your COVID-19 Test.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fstrong> Specifically, your firm received information indicating that the reagent packed in plastic tubes with screw-on caps were leaking. it is not clear how this complaint was received, reviewed, or evaluated; your firm has not established procedures to handle complaints, you have not kept records of any complaints received or investigated or evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to establish an organizational structure to ensure that devices are designed and produced in accordance 21 CFR part 820.20(b).\u003C\u002Fstrong> Specifically, you have not established an organizational structure that defines the responsibilities and authority, resources, management representative, management review, quality planning and quality system procedures in accordance with good manufacturing practices set forth in the Quality System Regulation.\u003Cbr>\n\u003Cbr>\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements. Notably, during the inspection, your firm acknowledged that it does not have any MDR procedures. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response dated July 6, 2022. In the response, your firm noted that you do not have certain “corrective action to propose” because you have “not manufactured test kits at the Holly Hill facility since July 2021,” and that you do “not plan to manufacture rapid antigen test kits in the near future.” However, as the manufacturer of those previously distributed devices your firm is still required under 21 CFR 803 to develop, maintain, and implement MDR procedures and ensure timely reporting of reportable events involving any device that you manufactured, even if you subsequently cease manufacturing or marketing the device. As such, your firm has an obligation to report adverse events.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to\u003C\u002Fstrong> COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale or distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter, in particular with respect to MDR procedures and reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. \u003Cstrong>Refer to CMS # 643203\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, \u003Cstrong>ORA Division Compliance Officer\u003C\u002Fstrong> at demetria.lueneburg@fda.hhs.gov \u003Cstrong>or 612-758-7210\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any violations at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nBlake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health\u003Cbr>\nDivision 2 Central\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-%20emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national- emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nElizabeth A. Lashinsky\n\nRecipient Title\n\nOwner\n\nNorth American Diagnostics, LLC\n\n618 Ridgewood Ave., Suite 100\n\nHolly Hill, FL 32117\n\nUnited States\n\nealash52@gmail.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 643203\n\nDecember 27, 2022\n\nDear Ms. Lashinsky:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations, North American Diagnostics, LLC (“North American,” “you,” or “your firm”), located at 618 Ridgewood Ave, Suite 100, Holly Hill, Florida on five dates from June 14 through 23, 2022. During this inspection, FDA investigators determined that your firm is a manufacturer and distributor of SARS-CoV-2 antigen rapid test kits under the names ORAL RAPID SARS-CoV-2 Antigen Rapid test kits, SDI LABS SARS-CoV-2 Antigen Rapid Test Kit, North American Diagnostics SARS-CoV-2 Antigen Rapid Test Kit, Skippack Medical Labs SARS-CoV-2 Antigen Rapid Test (Colloidal Gold), and Spectrum DX Lab SARS-CoV-2 Antigen Rapid test kits (hereafter referred to as “COVID-19 Test”). Based on our review, your COVID-19 Test is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, it is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h).\n\nOur inspection revealed that your COVID-19 test has been distributed in the United States (U.S.). without marketing approval, clearance, or authorization from FDA. Indeed, in your response dated July 6, 2022, concerning our investigators’ observations noted on the Form FDA 483 List of Inspectional Observations, that was issued to your firm, you acknowledged that you had “improperly distributed into commerce” COVID-19 test kits. Accordingly, your product is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your product is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of this product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)” provides FDA’s review priorities and enforcement policies regarding novel coronavirus (COVID-19) tests.\n\nThis inspection also revealed that your COVID-19 test is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed include:\n\n1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a). Specifically, your firm did not establish design control procedures prior to the manufacture and distribution of your COVID-19 test.\n\n2. Failure to develop, conduct, control, and monitor production processes to ensure the device conforms to its specifications, as required by 21 CDR 820.70. Specifically, your firm has not established production processes controls for your COVID-19 test, for any production and process changes, environmental control requirements, personnel requirements, contamination control requirements, manufacturing material requirements, or automated processes requirements.\n\n3. Failure to adequately ensure that the results of a process cannot be fully verified by subsequent inspection and test that the process shall be validated with a high degree of assurance and approved according to established procedure, as required by 21 CFR 820.75(a). Specifically, your firm has not conducted process validations for those processes that your firm cannot fully verify in the manufacture of your COVID-19 Test.\n\n4. Failure to establish procedures for acceptance activities, as required by 21 CFR 820.80. Specifically, your firm has not established 1) receiving acceptance activities for any components used to manufacture your COVID-19 Test, 2) in-process acceptance activities for any process critical to the functionality and\u002For intended use of the device, 3) final acceptance activities.\n\n5. Failure to establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm has not established procedures, instructions, or processes to identify, investigate, and correct problems that are observed and to prevent recurrence of issues.\n\n6. Failure to establish procedures for control and distribution of finished devices, as required by 21 CFR 820.160(a). Specifically, your firm does not have procedures for control and distribution of your COVID-19 Test.\n\n7. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm received information indicating that the reagent packed in plastic tubes with screw-on caps were leaking. it is not clear how this complaint was received, reviewed, or evaluated; your firm has not established procedures to handle complaints, you have not kept records of any complaints received or investigated or evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803.\n\n8. Failure to establish an organizational structure to ensure that devices are designed and produced in accordance 21 CFR part 820.20(b). Specifically, you have not established an organizational structure that defines the responsibilities and authority, resources, management representative, management review, quality planning and quality system procedures in accordance with good manufacturing practices set forth in the Quality System Regulation.\n\nOur inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. Specifically, your firm has not established procedures for timely and effective identification, communication, and evaluation of reportable events; a standardized review process for determining when an event meets reportability criteria; timely submission of MDRs to the FDA; or for compliance with the applicable documentation and recordkeeping requirements. Notably, during the inspection, your firm acknowledged that it does not have any MDR procedures. A device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, which includes adverse event reports required under 21 CFR Part 803, respecting the device.\n\nWe reviewed your firm’s response dated July 6, 2022. In the response, your firm noted that you do not have certain “corrective action to propose” because you have “not manufactured test kits at the Holly Hill facility since July 2021,” and that you do “not plan to manufacture rapid antigen test kits in the near future.” However, as the manufacturer of those previously distributed devices your firm is still required under 21 CFR 803 to develop, maintain, and implement MDR procedures and ensure timely reporting of reportable events involving any device that you manufactured, even if you subsequently cease manufacturing or marketing the device. As such, your firm has an obligation to report adverse events.\n\nYour firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-fdas-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any violations relating to your firm’s sale or distribution of the COVID-19 Test and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale or distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter, in particular with respect to MDR procedures and reporting. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 643203 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, ORA Division Compliance Officer at demetria.lueneburg@fda.hhs.gov or 612-758-7210.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any violations at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health\n\nDivision 2 Central\n\n______________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID‐19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national- emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","North American Diagnostics, LLC","north-american-diagnostics-llc-643203-12272022","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-diagnostics-llc-643203-12272022","2026-10-26T08:09:34.512211+00:00","Warning Letter","Issued","2023-04-18","643203","Medical Devices","Elizabeth A. Lashinsky","2026-08-20T01:09:41.813+00:00","VIA Electronic Mail","2022-12-27",{"id":32,"raw":33,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":18,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},2337,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2022-11-17T13:30:00Z\">11\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-14T05:00:00Z\">11\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbergamet-north-america-llc-636315-11142022\">BergaMet North America LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","New Drug\u002FMisbranded\u003Cbr \u002F>\r\n","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jay Decker\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>BergaMet North America LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6445 S. Tenaya Way Suite B110\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Las Vegas\u003C\u002Fspan>, \u003Cspan>NV\u003C\u002Fspan> \u003Cspan>89113-1989\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:orders@bergametna.com\"> orders@bergametna.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 14, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 636315\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jay Decker:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fbergametna.com in October 2022 and has determined that you take orders there for your Cholesterol Command product. We also reviewed your social media website,\u003Cbr>\nwww.facebook.com\u002FBergametNorthAmerica.com which directs consumers to your website, https:\u002F\u002Fbergametna.com to purchase your product. Additionally, we reviewed the product listing on www.walmart.com, where your product is available for purchase. The claims on your websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On your Cholesterol Command product page at https:\u002F\u002Fbergametna.com\u002Fproducts\u002Fcholesterol-command:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Anti-inflammatory”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Magnesium [an ingredient in Cholesterol Command] . . . Deficiency is related to . . . T2D [type 2 diabetes], chronic inflammation, heart disease and high blood pressure.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Zinc [an ingredient in Cholesterol Command] . . . This key mineral has specific properties that may address inflammatory or immune system conditions.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“WHEN YOU ORDER BERGAMET . . . Take our supplements with confidence knowing that if they do not improve your LDL levels. You get 100% of your money back down to the penny.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your “What is Bergamot” page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Flearn-about-bergamot:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Reduces cholesterol”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Anti-Inflammatory Citrus Bergamot [an ingredient in your Cholesterol Command product] has been clinically shown to reduce inflammation.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Walmart product page at https:\u002F\u002Fwww.walmart.com\u002Fip\u002FCitrus-Bergamot-Cholesterol-Command-80-Polyphenol-Formula-Supplement-Cholesterol-Heart-Health-Blood-Glucose-Levels-Highest-Strength\u002F543149759:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“BergaMet products follow the correct dosage and extract concentrations used and recommended in recent clinical studies as a bergamot supplement for high cholesterol . . . and help improve blood vessel function”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Cholesterol Command for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003Cbr>\n\u003Cbr>\nOn your testimonial page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Ftestimonials:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Love Cholesterol Command! My ldl is down 28 points, my doctor was extremely surprised because I am allergic to statins so working on my cholesterol levels has been difficult until I found out about BergaMet ... haven’t seen my cholesterol this low in 15 years”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your Facebook page at www.facebook.com\u002FBergametNorthAmerica.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;On a graphic titled “CAN CITRUS BERGAMOT [an ingredient in your Cholesterol Command product] IMPROVE YOUR CHOLESTEROL?” posted on March 14, 2022, you endorsed the following customer replies:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o “Yes, it really works! my bad cholesterol drooped by 60 pts . . .” You endorsed this testimonial by responding, “That is amazing Jon! Thank you for sharing.”\u003Cbr>\n&nbsp; o “I have had amazing results with this supplement it brought down all my levels out of the red and into a very healthy range … this is the answer not a statin!” You endorsed this testimonial by responding, “that is AMAZING Lori! Thank you for sharing and congrats!”\u003Cbr>\n&nbsp; o “That’s what I use I stopped taking my prescription and my lab test number are great.” You endorsed this testimonial by responding, “That is great to hear Emmanuel! Thank you for sharing”\u003Cbr>\n&nbsp; o You also endorsed the following responses to your post by liking them:\u003Cbr>\n&nbsp; &nbsp; 􀂃 “I just got my blood test back my total cholesterol went down 56 points and my bad cholesterol went down 82 points.”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Yes!! Mine went down 38 points.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Cholesterol Command product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Cholesterol Command is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Cholesterol Command fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003Cbr>\n\u003Cbr>\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jay Decker\n\nBergaMet North America LLC\n\n6445 S. Tenaya Way Suite B110\n\nLas Vegas, NV 89113-1989\n\nUnited States\n\norders@bergametna.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nNovember 14, 2022\n\nRE: 636315\n\nDear Mr. Jay Decker:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fbergametna.com in October 2022 and has determined that you take orders there for your Cholesterol Command product. We also reviewed your social media website,\n\nwww.facebook.com\u002FBergametNorthAmerica.com which directs consumers to your website, https:\u002F\u002Fbergametna.com to purchase your product. Additionally, we reviewed the product listing on www.walmart.com, where your product is available for purchase. The claims on your websites establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include the following:\n\nOn your Cholesterol Command product page at https:\u002F\u002Fbergametna.com\u002Fproducts\u002Fcholesterol-command:\n\n“BergaMet Cholesterol Command is clinically proven to improve cholesterol levels. It reduces LDL”\n\n“Anti-inflammatory”\n\n“Magnesium [an ingredient in Cholesterol Command] . . . Deficiency is related to . . . T2D [type 2 diabetes], chronic inflammation, heart disease and high blood pressure.”\n\n“Zinc [an ingredient in Cholesterol Command] . . . This key mineral has specific properties that may address inflammatory or immune system conditions.”\n\n“WHEN YOU ORDER BERGAMET . . . Take our supplements with confidence knowing that if they do not improve your LDL levels. You get 100% of your money back down to the penny.”\n\nOn your “What is Bergamot” page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Flearn-about-bergamot:\n\n“Reduces cholesterol”\n\n“Anti-Inflammatory Citrus Bergamot [an ingredient in your Cholesterol Command product] has been clinically shown to reduce inflammation.”\n\nOn your Walmart product page at https:\u002F\u002Fwww.walmart.com\u002Fip\u002FCitrus-Bergamot-Cholesterol-Command-80-Polyphenol-Formula-Supplement-Cholesterol-Heart-Health-Blood-Glucose-Levels-Highest-Strength\u002F543149759:\n\n“BergaMet products follow the correct dosage and extract concentrations used and recommended in recent clinical studies as a bergamot supplement for high cholesterol . . . and help improve blood vessel function”\n\nYour websites also contain evidence of intended use in the form of personal testimonials recommending or describing the use of Cholesterol Command for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\nOn your testimonial page at https:\u002F\u002Fbergametna.com\u002Fpages\u002Ftestimonials:\n\n“Love Cholesterol Command! My ldl is down 28 points, my doctor was extremely surprised because I am allergic to statins so working on my cholesterol levels has been difficult until I found out about BergaMet ... haven’t seen my cholesterol this low in 15 years”\n\nOn your Facebook page at www.facebook.com\u002FBergametNorthAmerica.com:\n\nOn a graphic titled “CAN CITRUS BERGAMOT [an ingredient in your Cholesterol Command product] IMPROVE YOUR CHOLESTEROL?” posted on March 14, 2022, you endorsed the following customer replies:\n\no “Yes, it really works! my bad cholesterol drooped by 60 pts . . .” You endorsed this testimonial by responding, “That is amazing Jon! Thank you for sharing.”\n\no “I have had amazing results with this supplement it brought down all my levels out of the red and into a very healthy range … this is the answer not a statin!” You endorsed this testimonial by responding, “that is AMAZING Lori! Thank you for sharing and congrats!”\n\no “That’s what I use I stopped taking my prescription and my lab test number are great.” You endorsed this testimonial by responding, “That is great to hear Emmanuel! Thank you for sharing”\n\no You also endorsed the following responses to your post by liking them:\n\n􀂃 “I just got my blood test back my total cholesterol went down 56 points and my bad cholesterol went down 82 points.”\n\n“Yes!! Mine went down 38 points.”\n\nYour Cholesterol Command product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Cholesterol Command is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Cholesterol Command fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration","BergaMet North America LLC","bergamet-north-america-llc-636315-11142022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbergamet-north-america-llc-636315-11142022","2026-10-26T08:08:03.414177+00:00","2022-11-17","636315","Dietary SupplementsDrugs","Mr. Jay Decker","2026-08-20T01:25:33.357+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-11-14",{"id":54,"raw":55,"subject":39,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":23,"posted_date":67,"marcs_cms_no":68,"product_type":69,"closeout_date":19,"issuing_office":59,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},3352,[56,57,58,59,39,13,13,13],"\u003Ctime datetime=\"2021-05-18T13:20:00Z\">05\u002F18\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-21T04:00:00Z\">04\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-hirudin-biotech-products-inc-613103-04212021\">North American Hirudin Biotech Products Inc.\u003C\u002Fa>","Office of Regulatory Affairs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Zengxun An\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Hirudin Biotech Products Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2531 Broadway, Suite A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Everett\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Regulatory Affairs\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 21, 2021\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 613103\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. An:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address http:\u002F\u002Fushirudin.com\u002F in February and April 2021, and has determined that you take orders there for your products “Hirudin” and “Red 65”. We also reviewed your websites at http:\u002F\u002Fwww.naturalhirudin.com\u002F and http:\u002F\u002Fbuyred65.com\u002F, both of which contain links to http:\u002F\u002Fushirudin.com\u002F where the products can be purchased. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hirudin\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the http:\u002F\u002Fushirudin.com\u002F website:\u003Cbr>\n• “Blood-thinning: Hirudin is a Natural Blood Thinner . . . help normalize the blood sugar level in your blood”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin . . . has unique abilities to . . . dissolve the . . . cholesterol in your blood so your blood flows unrestricted.”\u003C\u002Fp>\n\n\u003Cp>• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\u003C\u002Fp>\n\n\u003Cp>• “Is hirudin a potential therapeutic agent for arthritis?”\u003C\u002Fp>\n\n\u003Cp>• “[H]irudin . . . are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery . . . They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\u003C\u002Fp>\n\n\u003Cp>On the website http:\u002F\u002Fwww.naturalhirudin.com\u002F:\u003Cbr>\n• “Hirudin has been scientifically proven to be the most potent anti-coagulant.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin is . . . the most effective natural anticoagulant. Hirudin has been hailed as the promising molecule in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin . . . Hirudin has a system wide anticoagulation effect . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\u003C\u002Fp>\n\n\u003Cp>On the webpage for your Hirudin product at http:\u002F\u002Fushirudin.com\u002Fhirudin-the-original-formula\u002F:\u003Cbr>\n• “Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based. . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Benefits of Hirudin Tablet:\u003Cbr>\n&nbsp; &nbsp; o [N]aturally lowers cholesterol content from your blood system.\u003Cbr>\n&nbsp; &nbsp; o Blood-thinning . . . help normalize the blood sugar level in your blood.\u003Cbr>\n&nbsp; &nbsp; o [D]issolve the . . . cholesterol in your blood . . .\u003Cbr>\n&nbsp; &nbsp; o [S]trengthens your body’s defense capability against common viruses and bacteria.”\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Red 65\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the website http:\u002F\u002Fbuyred65.com\u002F:\u003Cbr>\n• “Red 65 blood cleanser for better heart health natural blood thinner natural lower cholesteral [sic] and natural prevent diabetes”\u003C\u002Fp>\n\n\u003Cp>• “[N]aturally lowers cholesterol content from your blood system.”\u003C\u002Fp>\n\n\u003Cp>• “Blood-thinning . . . help normalize the blood sugar level in your blood.”\u003C\u002Fp>\n\n\u003Cp>• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\u003C\u002Fp>\n\n\u003Cp>• “RED65 Offers Amazing Results for . . . Pain Relief . . . Anticoagulation - Binds Itself to Thrombins, Inhibiting Coagulation, Dissolving Existing Blood Clots . . . Blood Thinner . . . a Potent Anti-Coagulant that Thins the Blood . . . Vasodilator - Widens Vessel Walls . . .”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin [an ingredient in Red 65] has been scientifically proven to be the most potent anti-coagulant.”\u003C\u002Fp>\n\n\u003Cp>On the webpage for your Red 65 product at http:\u002F\u002Fushirudin.com\u002Fred-65-natural-blood-thinner\u002F:\u003Cbr>\n• “North American Hirudin Red 65 a Natural Blood Thinner . . .”\u003C\u002Fp>\n\n\u003Cp>• “Red 65 is a natural blood thinner . . . Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “. . . Red 65 is based on . . . its powers in promoting blood-thinning . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Benefits of Red 65:\u003Cbr>\n&nbsp; &nbsp; o Blood-thinning . . . help normalize the blood sugar level in your blood. Some diabetic patients have reported that Red65 is a natural diabetes control. Others have described Red65 as a natural Coumadin . . .\u003Cbr>\n&nbsp; &nbsp; o [D]issolve . . . cholesterol in your blood. . .\u003Cbr>\n&nbsp; &nbsp; o [S]trengthens your body’s defense capability against common viruses and bacteria.”\u003Cbr>\n\u003Cbr>\nOn the webpage titled “HOW DOES HIRUDIN DETOXIFY OUR BODIES?” at http:\u002F\u002Fushirudin.com\u002Fhow-does-hirudin-detoxify-our-bodies-2\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin. Hirudin has . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\u003C\u002Fp>\n\n\u003Cp>• “. . . hirudin specifically targets, prevents and dissolves the formation of clots . . . It is commonly used to treat other blood coagulation disorders, skin hematomas, and superficial varicose veins.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled “WHAT IS HIRUDIN AND WHAT DOES IT DO?” at http:\u002F\u002Fushirudin.com\u002Fwhat-is-hirudin-and-what-does-it-do\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “Since 1853 Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled “THE TABLET” at http:\u002F\u002Fushirudin.com\u002Fthe-tablet\u002F, which contains links to purchase Hirudin and Red 65 products:\u003Cbr>\n• “Hirudin has long been established in medical literature and research as a beneficial anticoagulant treatment . . ..”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin supplement tablet is . . . helping to maintain a normal blood pressure and blood sugar level which lowers the risk of developing cardiovascular and cerebrovascular diseases.”\u003C\u002Fp>\n\n\u003Cp>On the webpage titled: “Hirudin Evolution” at http:\u002F\u002Fushirudin.com\u002Fhirudin-evolution\u002F, which contains links to purchase Hirudin and Red65 products:\u003Cbr>\n• “Thrombosis is a major cause of death and disability from myocardial infarction, stroke, peripheral ischemia, and pulmonary embolism.”\u003C\u002Fp>\n\n\u003Cp>• “Hirudin is the most potent non-covalent inhibitor of thrombin.”\u003C\u002Fp>\n\n\u003Cp>• “[Hirudin and synthetic analogues of hirudin] are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery. They are also used as adjunct to fibrinolytic therapy. They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\u003C\u002Fp>\n\n\u003Cp>Your “Hirudin” and “Red 65” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your “Hirudin” and “Red 65” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, “Hirudin” and “Red 65” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Miriam R. Burbach\u003Cbr>\nDistrict Director\u003Cbr>\nProgram Division Director\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Delivery\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nZengxun An\n\nRecipient Title\n\nPresident\n\nNorth American Hirudin Biotech Products Inc.\n\n2531 Broadway, Suite A\n\nEverett, WA 98201\n\nUnited States\n\nIssuing Office:\n\nOffice of Regulatory Affairs\n\nUnited States\n\nApril 21, 2021\n\nIn reply, refer to CMS 613103\n\nWARNING LETTER\n\nDear Mr. An:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address http:\u002F\u002Fushirudin.com\u002F in February and April 2021, and has determined that you take orders there for your products “Hirudin” and “Red 65”. We also reviewed your websites at http:\u002F\u002Fwww.naturalhirudin.com\u002F and http:\u002F\u002Fbuyred65.com\u002F, both of which contain links to http:\u002F\u002Fushirudin.com\u002F where the products can be purchased. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nHirudin\n\nOn the http:\u002F\u002Fushirudin.com\u002F website:\n\n• “Blood-thinning: Hirudin is a Natural Blood Thinner . . . help normalize the blood sugar level in your blood”\n\n• “Hirudin . . . has unique abilities to . . . dissolve the . . . cholesterol in your blood so your blood flows unrestricted.”\n\n• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\n\n• “Is hirudin a potential therapeutic agent for arthritis?”\n\n• “[H]irudin . . . are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery . . . They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\n\nOn the website http:\u002F\u002Fwww.naturalhirudin.com\u002F:\n\n• “Hirudin has been scientifically proven to be the most potent anti-coagulant.”\n\n• “Hirudin is . . . the most effective natural anticoagulant. Hirudin has been hailed as the promising molecule in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning . . ..”\n\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin . . . Hirudin has a system wide anticoagulation effect . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\n\nOn the webpage for your Hirudin product at http:\u002F\u002Fushirudin.com\u002Fhirudin-the-original-formula\u002F:\n\n• “Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based. . . its powers in promoting blood-thinning . . ..”\n\n• “Benefits of Hirudin Tablet:\n\no [N]aturally lowers cholesterol content from your blood system.\n\no Blood-thinning . . . help normalize the blood sugar level in your blood.\n\no [D]issolve the . . . cholesterol in your blood . . .\n\no [S]trengthens your body’s defense capability against common viruses and bacteria.”\n\nRed 65\n\nOn the website http:\u002F\u002Fbuyred65.com\u002F:\n\n• “Red 65 blood cleanser for better heart health natural blood thinner natural lower cholesteral [sic] and natural prevent diabetes”\n\n• “[N]aturally lowers cholesterol content from your blood system.”\n\n• “Blood-thinning . . . help normalize the blood sugar level in your blood.”\n\n• “[S]trengthens your body’s defense capability against common viruses and bacteria.”\n\n• “RED65 Offers Amazing Results for . . . Pain Relief . . . Anticoagulation - Binds Itself to Thrombins, Inhibiting Coagulation, Dissolving Existing Blood Clots . . . Blood Thinner . . . a Potent Anti-Coagulant that Thins the Blood . . . Vasodilator - Widens Vessel Walls . . .”\n\n• “Hirudin [an ingredient in Red 65] has been scientifically proven to be the most potent anti-coagulant.”\n\nOn the webpage for your Red 65 product at http:\u002F\u002Fushirudin.com\u002Fred-65-natural-blood-thinner\u002F:\n\n• “North American Hirudin Red 65 a Natural Blood Thinner . . .”\n\n• “Red 65 is a natural blood thinner . . . Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “. . . Red 65 is based on . . . its powers in promoting blood-thinning . . ..”\n\n• “Benefits of Red 65:\n\no Blood-thinning . . . help normalize the blood sugar level in your blood. Some diabetic patients have reported that Red65 is a natural diabetes control. Others have described Red65 as a natural Coumadin . . .\n\no [D]issolve . . . cholesterol in your blood. . .\n\no [S]trengthens your body’s defense capability against common viruses and bacteria.”\n\nOn the webpage titled “HOW DOES HIRUDIN DETOXIFY OUR BODIES?” at http:\u002F\u002Fushirudin.com\u002Fhow-does-hirudin-detoxify-our-bodies-2\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “In the early days of the twentieth century, medical pioneers used leeches to treat cardiovascular disease primarily due to the natural anticoagulant, hirudin. Hirudin has . . . mechanisms that contribute to the treatment of cardiovascular diseases or conditions such as a stroke or a heart attack.”\n\n• “. . . hirudin specifically targets, prevents and dissolves the formation of clots . . . It is commonly used to treat other blood coagulation disorders, skin hematomas, and superficial varicose veins.”\n\nOn the webpage titled “WHAT IS HIRUDIN AND WHAT DOES IT DO?” at http:\u002F\u002Fushirudin.com\u002Fwhat-is-hirudin-and-what-does-it-do\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “Since 1853 Hirudin has been recognized by scientists and medical professionals alike as the most effective natural anticoagulant. Hirudin has been hailed . . . in the fight against cardiovascular and blood-related disease.”\n\n• “Hirudin Tablet is based on . . . its powers in promoting blood-thinning.”\n\nOn the webpage titled “THE TABLET” at http:\u002F\u002Fushirudin.com\u002Fthe-tablet\u002F, which contains links to purchase Hirudin and Red 65 products:\n\n• “Hirudin has long been established in medical literature and research as a beneficial anticoagulant treatment . . ..”\n\n• “Hirudin supplement tablet is . . . helping to maintain a normal blood pressure and blood sugar level which lowers the risk of developing cardiovascular and cerebrovascular diseases.”\n\nOn the webpage titled: “Hirudin Evolution” at http:\u002F\u002Fushirudin.com\u002Fhirudin-evolution\u002F, which contains links to purchase Hirudin and Red65 products:\n\n• “Thrombosis is a major cause of death and disability from myocardial infarction, stroke, peripheral ischemia, and pulmonary embolism.”\n\n• “Hirudin is the most potent non-covalent inhibitor of thrombin.”\n\n• “[Hirudin and synthetic analogues of hirudin] are alternatives to heparin for the treatment of: 1) unstable angina, 2) abrupt closure and restenosis following coronary angioplasty, and 3) prevention of deep vein thrombosis after major orthopedic surgery. They are also used as adjunct to fibrinolytic therapy. They are fast becoming the drugs of choice for the anticoagulant treatment of patients with heparin-induced thrombocytopenia with thromboembolic complications.”\n\nYour “Hirudin” and “Red 65” products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d) and § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Hirudin” and “Red 65” products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, “Hirudin” and “Red 65” products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director\n\nProgram Division Director","North American Hirudin Biotech Products Inc.","north-american-hirudin-biotech-products-inc-613103-04212021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-hirudin-biotech-products-inc-613103-04212021","2026-10-26T08:09:34.567247+00:00","2021-05-18","613103","Drugs","Zengxun An","2026-08-20T03:08:12.347+00:00","Overnight Delivery","2021-04-21",{"id":75,"raw":76,"subject":81,"body_html":83,"body_text":84,"firm_name":85,"letter_id":86,"created_at":18,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":89,"posted_date":90,"marcs_cms_no":91,"product_type":69,"closeout_date":92,"issuing_office":93,"recipient_name":94,"body_fetched_at":95,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},2238,[77,78,79,80,81,13,82,13],"\u003Ctime datetime=\"2023-01-24T14:20:00Z\">01\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-18T05:00:00Z\">11\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-11182022\">North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations II ","Compounding Pharmacy\u002FAdulterated Drug Products","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-01272026\">\u003Ctime datetime=\"2026-03-20T04:00:00Z\">03\u002F20\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Justin K. Graves\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1736 North Greenville Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Richardson\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75081-1808\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations II \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 11\u002F18\u002F2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Case #: 642792\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Graves,\u003C\u002Fp>\n\n\u003Cp>From March 1, 2022, to March 10, 2022, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding, located at 1736 North Greenville Avenue, Richardson, TX 75081. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your firm on March 10, 2022. FDA acknowledges receipt of your facility’s response, dated March 30, 2022, as well as your subsequent correspondence. FDA acknowledges that your firm initiated a voluntary recall of drug products that are intended to be sterile on April 5, 2022. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Section 503A of the FDCA [21 U.S.C. § 353a] describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003Cbr>\n\u003Cbr>\n\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The FDA investigator noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\u003C\u002Fp>\n\n\u003Cp>1. Your firm used a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the purposes of product sterilization that was not appropriate for pharmaceutical use and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing was inadequate. Therefore, you do not have assurance that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was integral throughout use.\u003C\u002Fp>\n\n\u003Cp>2. Your firm did not adequately disinfect materials or supplies during transfer from the ISO 8 cleanroom into higher classification areas.\u003C\u002Fp>\n\n\u003Cp>3. Your firm handled hazardous drug products without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\n\n\u003Cp>5. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\n\n\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response to the Form FDA 483. Regarding your response related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\u003C\u002Fp>\n\n\u003Cp>1. In your response to Observation 1 of the Form FDA 483, we acknowledge your firm’s statement that you have regained supply of and resumed use of previously unavailable \u003Cstrong>(b)(4)\u003C\u002Fstrong> for “immediate use sterile subcutaneous injectable compounding” at your facility. However, you did not provide sufficient evidence of the corrective actions, such as purchase orders, current batch records (i.e., formula work sheets), or \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing procedures for the newly acquired \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>2. Regarding the pink residue on the ceiling, vents, and walls in your production area as described in Observation 5 of the Form FDA 483, you provided your revised SOP, 02-CPCP-12 \u003Cem>Non-Sterile Hazardous Compound – Hormone Only&nbsp;\u003C\u002Fem>and committed to “attempting a deep scrubbing of the room.” It is unclear if this cleaning was attempted and\u002For effective to remediate this observation or if your revised procedures have prevented reoccurrence.\u003C\u002Fp>\n\n\u003Cp>3. In your response to Observation 7 of the Form FDA 483, we acknowledge your firm’s statement that, “Moving forward, when smoke studies are conducted, footage from video will record, in detail, the dynamic compounding of sterile compounding in a PEC.” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such as an updated smoke study protocol or an updated detailed report, and\u002For video.\u003C\u002Fp>\n\n\u003Cp>4. In your response to Observation 8 of the Form FDA 483, we acknowledge your firm’s statement that, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such updated media fill protocol or results.\u003C\u002Fp>\n\n\u003Cp>In addition, from review of the evidence collected during the inspection, your October 26, 2021, \u003Cem>Environmental Monitoring Report\u003C\u002Fem> lists your action level for the ISO 5 area as&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fm\u003Csup>3\u003C\u002Fsup> for “Air Test” and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fplate for “Surface Test.” Please note that any microbial contamination in the ISO 5 area is a serious concern and considered an insanitary condition. If any ISO 5 recovery occurs, your firm should immediately assess the impact on drug products produced. This assessment should include a thorough evaluation of how contamination could have entered this critical area, and over what period of time the contamination could have existed, as well as drug products that remain on the market that could have been affected.\u003C\u002Fp>\n\n\u003Cp>Please be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time in which you will do so.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case number 642792.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Shawn Larson, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov and Shawn.Larson@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Dr. Larson via phone at 214-253-5216 or email at Shawn.Larson@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Justin K. Graves\n\nRecipient Title\n\nVice President\n\nNorth American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding\n\n1736 North Greenville Avenue\n\nRichardson, TX 75081-1808\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nDATE: 11\u002F18\u002F2022\n\nCase #: 642792\n\nWARNING LETTER\n\nDear Mr. Graves,\n\nFrom March 1, 2022, to March 10, 2022, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding, located at 1736 North Greenville Avenue, Richardson, TX 75081. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\n\nFDA issued a Form FDA 483 to your firm on March 10, 2022. FDA acknowledges receipt of your facility’s response, dated March 30, 2022, as well as your subsequent correspondence. FDA acknowledges that your firm initiated a voluntary recall of drug products that are intended to be sterile on April 5, 2022. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\n\nA. Compounded Drug Products Under the FDCA\n\nSection 503A of the FDCA [21 U.S.C. § 353a] describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1\n\nB. Violations of the FDCA\n\nAdulterated Drug Products\n\nThe FDA investigator noted that drug products were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\n\n1. Your firm used a (b)(4) for the purposes of product sterilization that was not appropriate for pharmaceutical use and the (b)(4) testing was inadequate. Therefore, you do not have assurance that the (b)(4) was integral throughout use.\n\n2. Your firm did not adequately disinfect materials or supplies during transfer from the ISO 8 cleanroom into higher classification areas.\n\n3. Your firm handled hazardous drug products without providing adequate containment, segregation, or cleaning of work surfaces and utensils to prevent cross-contamination.\n\n4. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\n\n5. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nC. Corrective Actions\n\nWe have reviewed your firm’s response to the Form FDA 483. Regarding your response related to the insanitary conditions, some of your corrective actions appear adequate; however, we cannot fully evaluate the adequacy of the following corrective actions described in your response because you did not include sufficient information or supporting documentation:\n\n1. In your response to Observation 1 of the Form FDA 483, we acknowledge your firm’s statement that you have regained supply of and resumed use of previously unavailable (b)(4) for “immediate use sterile subcutaneous injectable compounding” at your facility. However, you did not provide sufficient evidence of the corrective actions, such as purchase orders, current batch records (i.e., formula work sheets), or (b)(4) testing procedures for the newly acquired (b)(4).\n\n2. Regarding the pink residue on the ceiling, vents, and walls in your production area as described in Observation 5 of the Form FDA 483, you provided your revised SOP, 02-CPCP-12 Non-Sterile Hazardous Compound – Hormone Only and committed to “attempting a deep scrubbing of the room.” It is unclear if this cleaning was attempted and\u002For effective to remediate this observation or if your revised procedures have prevented reoccurrence.\n\n3. In your response to Observation 7 of the Form FDA 483, we acknowledge your firm’s statement that, “Moving forward, when smoke studies are conducted, footage from video will record, in detail, the dynamic compounding of sterile compounding in a PEC.” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such as an updated smoke study protocol or an updated detailed report, and\u002For video.\n\n4. In your response to Observation 8 of the Form FDA 483, we acknowledge your firm’s statement that, “(b)(4).” However, we cannot fully evaluate your response as you did not provide sufficient supporting documentation, such updated media fill protocol or results.\n\nIn addition, from review of the evidence collected during the inspection, your October 26, 2021, Environmental Monitoring Report lists your action level for the ISO 5 area as (b)(4) cfu\u002Fm3 for “Air Test” and (b)(4) cfu\u002Fplate for “Surface Test.” Please note that any microbial contamination in the ISO 5 area is a serious concern and considered an insanitary condition. If any ISO 5 recovery occurs, your firm should immediately assess the impact on drug products produced. This assessment should include a thorough evaluation of how contamination could have entered this critical area, and over what period of time the contamination could have existed, as well as drug products that remain on the market that could have been affected.\n\nPlease be aware that section 501(a)(2)(A) of the FDCA concerning insanitary conditions applies regardless of whether drug products you compound meet the conditions of section 503A.\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug processing expertise should assist you in conducting this comprehensive evaluation.\n\nD. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time in which you will do so.\n\nYour written notification should refer to case number 642792.\n\nPlease electronically submit your reply, on company letterhead, to Shawn Larson, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov and Shawn.Larson@fda.hhs.gov\n\nIf you have questions regarding the contents of this letter, you may contact Dr. Larson via phone at 214-253-5216 or email at Shawn.Larson@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\n__________________________\n\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.","North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding","north-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-11182022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnorth-american-custom-laboratories-llc-dba-farmakeio-superior-custom-compounding-642792-11182022","2026-10-26T08:09:34.465242+00:00","Closed Out","2023-01-24","642792","2026-03-20","Division of Pharmaceutical Quality Operations II","Mr. Justin K. Graves","2026-08-20T01:18:42.458+00:00","2022-11-18",{"id":98,"raw":99,"subject":104,"body_html":105,"body_text":106,"firm_name":107,"letter_id":108,"created_at":109,"fei_number":19,"letter_url":110,"updated_at":111,"action_type":22,"case_status":23,"posted_date":112,"marcs_cms_no":19,"product_type":69,"closeout_date":19,"issuing_office":113,"recipient_name":114,"body_fetched_at":115,"delivery_method":116,"recipient_title":19,"reference_number":19,"action_taken_date":117,"medical_device_id":19,"response_letter_date":19},1837,[100,101,102,103,104,13,13,13],"\u003Ctime datetime=\"2023-09-19T13:20:00Z\">09\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-01T04:00:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national\">Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East VI","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Maria S. LeMay-Bey, Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Isaiah Orton-Bey, Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16136 W. 7 Mile Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Detroit\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48235\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Moorherbs13@gmail.com\"> Moorherbs13@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS Case #655674\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 1, 2023\u003Cbr>\n\u003Cbr>\nDear Isaiah Orton-Bey and Maria LeMay-Bey:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) has conducted an inspection of your manufacturing facility at 16136 W. 7 Mile Road, Livonia, MI 48235-2903 from February 13, 2023 to March 16, 2023. Additionally, FDA reviewed your website at https:\u002F\u002Fmoorherbs.com in May 2023. The inspection and our review of your website revealed serious violations of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) and FDA regulations. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your response to the FDA 483 on April 3, 2023. We address your response below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs and Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website, https:\u002F\u002Fmoorherbs.com, in May 2023 and has determined that you take orders there for the products “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Appendix Support,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Cardiovascular System,” “Headache &amp; Pain Relief,” “Healthy Mommy Healthy Baby,” “Quit Smoking,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThyroidism” (also referred to as “HypoThyroid Support”), “Mucus Release,” “Parasite Cleanse,” “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Un-Vax,” “Venereal Defense,” “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”), and “Lungs &amp; Respiratory.” The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>\u003Cbr>\nOn the “Full Body Antibiotic” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Full Body Antibiotic” or “AntiBiotic, Full Body”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ AntiBiotic Formulae targets it all! Use it to help heal respiratory and sinus infections, bronchitis, pneumonia, strep throat, colds, flues [sic], colic, seizures, cough, diabetes, urinary problems, menstrual problems, fever, liver problems, constipation, vaginal discharge, smallpox, enlarged spleen, swelling, asthma, eye cataracts, depression, digestion problems, stomach ulcers, heart trouble, infections, migraine, stroke, pain, . . . as well as urinary tract, kidney, and bladder infections.”\u003Cbr>\n• “Also beneficial for women with yeast infections, trichonomosas, bacterial vaginosis, and chlamydia.”\u003Cbr>\n• “It can be helpful for people with chronic fatigue, HIV, cancer, herpes, and other chronic conditions related with depressed immunity.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Anti-Viral”\u003C\u002Fu>\u003Cbr>\nOn the “Anti-Viral” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Anti-Viral”\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Anti-Viral Formulae is a potent and effective herbal anti-viral conducive for countering all viral conditions.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Appendix Support”\u003C\u002Fu>\u003Cbr>\nOn the “Appendix Support” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs High Science Appendix Support herbal blend is formulated to address the issues that lead to appendicitis: Constipation, Inflammation, and Infection.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Blood Pressure” (also referred to as “Blood Pressure Normalizer”)\u003C\u002Fu>\u003Cbr>\nOn the “Blood Pressure” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Blood Pressure Normalizer”\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Blood Pressure Normalizor [sic] is supported by an Indian medicinal herb belonging to Caesalpiniaceae family of plants.…What makes these seeds really popular, is their ability to lower blood pressure. Acting as a hypotensive agent, this humble seed works wonders for those looking to control their BP naturally.”\u003Cbr>\n• “It is a strong anti bacterial agent...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Brain Tune-Up”\u003C\u002Fu>\u003Cbr>\nOn the “Brain Tune-Up” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “The 2 main ingredients in this blend are Gotu Kola and Ginko Biloba[.] Gotu Kola Leaf… is anti-inflammatory, antiviral, antibacterial, . . . and antifungal. In human studies, gotu kola . . . reduced symptoms of anxiety and depression. It has been used to treat brain-related disorders including mental fatigue, anxiety, depression, memory loss, and insomnia.”\u003Cbr>\n• “Protects the brain from damage”\u003Cbr>\n• “Alleviates stress, anxiety, and depression”\u003Cbr>\n• “Improves memory and mood in Alzheimer’s patients”\u003Cbr>\n• “Ginko Biloba has been repeatedly evaluated for its ability to reduce anxiety, stress and other symptoms associated with Alzheimer’s disease …”\u003Cbr>\n• “Can Help Fight Inflammation.”\u003Cbr>\n• “Reduces Symptoms of Psychiatric Disorders and Dementia.”\u003Cbr>\n• “Can Reduce Anxiety.”\u003Cbr>\n• “Can Treat Depression.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Cardiovascular System”\u003C\u002Fu>\u003Cbr>\nOn the “Cardiovascular System” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “This ‘High Science’ Formula is designed to rebuild a degenerative heart...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Headache &amp; Pain Relief”\u003C\u002Fu>\u003Cbr>\nOn the “Headache &amp; Pain Relief” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Headache &amp; Pain Relief”\u003Cbr>\n• “Our Headache and Pain formula is a natural anodyne concoction that contains plants naturally rich in salicin that naturally breaks down into salicylic acid in the body that is anti-inflammatory in nature and thus effective where there is pain, which is a sensor that something is wrong on a deeper level.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Healthy Mommy Healthy Baby”\u003C\u002Fu>\u003Cbr>\nOn the “Healthy Mommy Healthy Baby” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Note: This blend is also helpful for the following conditions: anemia, low blood, arthritis, asthma, hay fever, sinusitis, gout, emphysema, bronchitis, sinus relief, allergies, high blood pressure, nosebleeds, hemorrhaging, miscarriage (vitamin K), hardened arteries, tooth decay, peptic ulcers, duodenum ulcers, infections, drug and chemical toxins, skin problems, edema, water retention, bowels, gas pains...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Quit Smoking”\u003C\u002Fu>\u003Cbr>\nOn the “Quit Smoking” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Quit Smoking”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Quit Smoking Formulae is a herbal compound of Nature’s best herbs that have been utilized traditionally to help purify the bloodstream of pollutants and toxins, cleanse the liver…and develop a distaste of insidious addictive man- chemicals.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“HyperThyroidism” (also referred to as “HyperThyroid Support”)\u003C\u002Fu>\u003Cbr>\nOn the “HyperThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “HyperThyroidism” or “HyperThyroid Support”\u003Cbr>\n• “For an overactive Thyroid”\u003Cbr>\n• “Moor Herbs High Science HyperThyroidism Relief Formulae is designed for an over-active thyroid gland. Effective for calming down an overactive thyroid and reducing symptoms of hyperthyroidism such as agitation, restlessness, sweating and insomnia.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“HypoThyroidism” (also referred to as “HypoThyroid Support”)\u003C\u002Fu>\u003Cbr>\nOn the “HypoThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “HypoThyroidism” or “HypoThyroid Support”\u003Cbr>\n• “For an underactive Thyroid”\u003Cbr>\n• “Moor Herbs High Science Thyroid Support Formula consists of Nature’s plants high in organic iodine and which perform a myriad of beneficial functions for the thyroid gland including…normalizing the function of metabolism. An impaired thyroid gland can lead to a host of negative health problems so good thyroid health is imperative for overall good health.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Mucus Release”\u003C\u002Fu>\u003Cbr>\nOn the “Mucus Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Mucus Release is a powerful ‘High Science’ formula that consists of effective expectorant herbs that help dissolve hardened, stubborn mucus and phlegm that obstruct the mucous membranes and lead to pathology throughout the body…Mucus Release is great for all mucus conditions!”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Parasite Cleanse”\u003C\u002Fu>\u003Cbr>\nOn the “Parasite Cleanse” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Parasite Cleanse”\u003Cbr>\n• “Parasite Cleanse ‘High Science’ Formula contain[s] some of Nature’s best anthelmintic herbs that have been traditionally used for centuries by various cultures to remove parasites and worms from the tissues of the body. These creepy critters most certainly rob the body of nutrients and impair critical functions of the organs, glands, and systems of the body.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“ResErection Extra Strength w\u002F Yohimbe Bark”\u003C\u002Fu>\u003Cbr>\nOn the “ResErection Extra Strength w\u002F Yohimbe Bark” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Resurrection formulae, is a 100% all-natural herbal-based formula for men experiencing difficulty with attaining and maintaining an erection (penile erectile dysfunction) with the root cause being poor circulation due to poor diet (and lifestyle) – a diet too high in animal protein (meat, flesh, cadavaer, carion, etc.) and animal fat which clogs the veins and arteries and thus impairing circulation which is vital for a healthy, solid, firm, and stiff erection.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Tumor Release” (also referred to as “Tumor &amp; Cyst Support”)\u003C\u002Fu>\u003Cbr>\nOn the “Tumor Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Tumor Release” or “Tumor &amp; Cyst Support”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Tumor Release Formulae is a safe, sane and effective plant-based anti-neoplastic formulae that is helpful in natural, noninvasive, benign and malignant tumor dissolution.”\u003Cbr>\n• “The formula is useful for all tumor and cyst formations in the body, including uterine and ovarian cysts\u002Ftumors. Good for both internal and external tumors.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Un-Vax”\u003C\u002Fu>\u003Cbr>\nOn the “Un-Vax” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Herbal UN-VAX Formulae is an unique formula designed to remove heavy metal toxins from the body. It is an ideal Formulae to combat mercury (ethyl and methyl) toxicity and aluminum toxicity, both of which are known to cause a plethora of adverse health conditions, especially in children.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Venereal Defense”\u003C\u002Fu>\u003Cbr>\nOn the “Venereal Defense” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Venereal Defense”\u003Cbr>\n• “Our Moor Herbs High Science Venereal Defense Formulae helps foment natural healing of adverse conditions that are passed on from one person to another through intimate contact.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”)\u003C\u002Fu>\u003Cbr>\nOn the “Womb Care Cramp Relief &amp; Fibroid Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Womb Care Cramp Relief &amp; Fibroid Release” or “Womb Care: Fibroid and Tumor Release”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Fibroid\u002FTumor Release Formulae is an all-natural herbal formulation consisting of Nature’s herbs that have an affinity for the female uterus, e.g. Chaste berry and Dong Quai and that are also anti-neoplastic (anti-tumor growth and formation) in nature, e.g. Burdock and Comfrey, thus combating tumorous growth on the uterus, e.g. fibroid tumors or uterine fibroids, facilitating dissolution via the vaginal canal and other eliminative channels.”\u003Cbr>\n• “Fibroids\u002FTumor Release, is a product that can be used in an overall regimen to help females naturally dissolve tumors of the reproductive system and is a great post Womb Cleanse formulae to consume daily.”\u003Cbr>\n• “Recommended for: Uterine fibroids or fibroid tumors, cervical tumors, uterine cysts.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Lungs &amp; Respiratory”\u003C\u002Fu>\u003Cbr>\nOn the “Lungs &amp; Respiratory” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003C\u002Fp>\n\n\u003Cp>• “This High Science Formula is a highly effective anti-tussive and expectorant science formulae.”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act [21 U.S.C. 321(p)].\u003C\u002Fp>\n\n\u003Cp>With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The dietary supplements manufactured at your facility are adulterated under section 402(g)(1) of the FD&amp;C Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111). During the inspection of your facility, FDA investigators observed the following significant violations of the CGMP regulation for dietary supplements:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish the specifications required under 21 CFR 111.70. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. You failed to establish the following required component specifications under 21 CFR 111.70(b) for each component that you use in the manufacture of a dietary supplement: (1) identity specifications, as required by 21 CFR 111.70(b)(1); and (2) component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, when our investigators requested such component specifications for the Coltsfoot, Wild Cherry Bark, and Boneset Herb ingredients used in the manufacturing of your “Lungs &amp; Respiratory” finished dietary supplement product, you were unable to provide such component specifications. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing component specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>b. You failed to establish specifications for dietary supplement labels (labeling specifications), as required by 21 CFR 111.70(d). Specifically, you were unable to provide labeling specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you are in the process of establishing written labeling specifications. We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>c. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you were unable to provide finished product specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing product specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>We note that once you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, once you have established component specifications and before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c).\u003C\u002Fp>\n\n\u003Cp>You must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103, and make and keep records of such procedures, as required by 21 CFR 111.140(b)(1). Specifically, you told our investigators that you have no written procedures for quality control operations and that you do not have a quality control program in place.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of implementing quality control operations to ensure the quality of dietary supplements” and “are also in the process of establishing written procedures and training quality control personnel to ensure all is produced safely, accurately, and according to the standards we have, and are putting, in place.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>3. You did not prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Upon request, you could not provide written MMRs for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products to our investigators. You stated that you did not have these records, and none were provided.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of establishing Master Manufacturing Records for each dietary supplement and size.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>4. Your batch production record did not include complete information relating to the production and control of each batch, as required under 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, batch production records for “Anti-Viral” manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”) manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and “Lungs &amp; Respiratory” manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, were collected and reviewed. These records do not include complete information required to be in batch production records. The required information that your records are missing includes, but is not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)];\u003Cbr>\n• The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)]; The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)];\u003Cbr>\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)];\u003Cbr>\n• The actual results obtained during any monitoring operation [21 CFR 111.260(g)];\u003Cbr>\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\u003Cbr>\n• Documentation at the time of performance of the manufacture of the batch, including [21 CFR 111.260(j)]:\u003Cbr>\no The date on which each step of the MMR was performed [21 CFR 111.260(j)(1)]; and\u003Cbr>\no The initials of the persons performing each step [21 CFR 111.260(j)(2)], including:\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for weighing or measuring each component used in the batch;\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for verifying the weight or measure of each component used in the batch;\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for adding the component to the batch; and\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for verifying the addition of components to the batch;\u003Cbr>\n• Documentation at the time of performance of packaging and labeling operations [21 CFR 111.260(k)], including:\u003Cbr>\n&nbsp; &nbsp; o The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels [21 CFR 111.260(k)(1)];\u003Cbr>\n&nbsp; &nbsp; o An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the MMR [21 CFR 111.260(k)(2)]; and\u003Cbr>\n&nbsp; &nbsp; o The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)(3)];\u003Cbr>\n• Documentation at the time of performance that quality control personnel [21 CFR 111.260(l):\u003Cbr>\n&nbsp; &nbsp; o Reviewed the batch production record [21 CFR 111.260(l)(1), including:\u003Cbr>\n Review of any monitoring operation required under subpart E of 21 CFR part 111 [21 CFR 111.260(l)(i)]; and\u003Cbr>\n Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements [21 CFR 111.260(l)(ii)];\u003Cbr>\n&nbsp; &nbsp; o Approved or rejected any reprocessing or repackaging [21 CFR 111.260(l)(2)]; and\u003Cbr>\n&nbsp; &nbsp; o Approved and released, or rejected, the batch for distribution, including any reprocessed batch [21 CFR 111.260(l)(3)]; and\u003Cbr>\n&nbsp; &nbsp; o Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement [21 CFR 111.260(l)(4)].\u003Cbr>\n• Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)];\u003Cbr>\n• Documentation at the time of performance of any reprocessing [21 CFR 111.260(n)].\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are still in the process of establishing and implementing the systems (as discussed throughout this document and the investigators observations) that will allow us to produce complete batch records.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>5. You failed to establish and follow written procedures for the requirements to review and investigate a product complaint, as required under 21 CFR 111.553. Specifically, our investigators requested your written procedures to review and investigate a product complaint. You stated that you did not have this procedure, and you did not provide it.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state, “We’ve been operating since March of 2015 and have never received a complaint. However, we are in the process of establishing written procedures for reviewing and investigating product\u002Fcustomer complaints.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>6. You failed to establish and follow written procedures for when a returned dietary supplement is received, as required under 21 CFR 111.503. Specifically, our investigators requested your written procedures for when a returned dietary supplement is received. You stated that you did not have these written procedures, and none were provided.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for when a returned dietary supplement is received.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>7. You failed to establish and follow written procedures for holding and distributing operations, as required by 21 CFR 111.453. Specifically, during the inspection, you said you had not established written procedures for holding and distributing operations.\u003C\u002Fp>\n\n\u003Cp>Once have you established written procedures for your holding and distributing operations, you must make and keep records of such written procedures, as required by 21 CFR 111.475(b)(1).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for holding and distributing operations.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>8. You did not maintain and clean equipment, utensils, and contact surfaces used to manufacture, package, label, or hold components or dietary supplements, as required under 21 CFR 111.27(d). P\u003C\u002Fp>\n\n\u003Cp>Specifically, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, during the manufacturing of your “Lungs &amp; Respiratory” finished dietary supplement product, your multi-functional grinder was observed with a light green and brown residue inside the bowl and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> plastic capsule filling equipment was observed with a light brown powder and brown staining. Furthermore, the method you used for cleaning and sanitizing your utensils and equipment does not align with, and directly contradicts, the manufacturer’s written instructions on the cleaning and sanitizing products. Additionally, you do not have any written procedures for cleaning or sanitizing your utensils and equipment, as required under 21 CFR 111.25(c).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “have since corrected the way we wash and sanitize our utensils and equipment, according to the instructions indicated on the cleaning agents we use, combined with regulations outlined under Michigan Food Law.” These corrections will be evaluated during the next FDA inspection of your firm. You also stated in your response that you “are in the process of establishing written procedures for cleaning and sanitizing utensils and equipment.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”),, “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded dietary supplements under Section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101 as follows:\u003C\u002Fp>\n\n\u003Cp>1. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the labels is are incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Lungs and Respiratory, Full Body Antibiotic, Antiviral, Blood Pressure Normalizer, Headache &amp; Pain Relief, and Bright Eyes product labels’ serving sizes is declared as “3 Capsules or 3 Scoops” and are not specific to each product.\u003C\u002Fp>\n\n\u003Cp>2. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of sections 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling of the products does not comply with 21 CFR 101.36. Specifically,\u003Cbr>\n• The title “Supplement Facts” is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\u003Cbr>\n• The dietary ingredients are not indented under the title “Proprietary Herbal Blend”, in accordance with 21 CFR 101.36(c)(2).\u003Cbr>\n• The quantitative amount by weight per serving of proprietary blend does not use metric measures in appropriate units (i.e., 1000 units must be declared in the next higher set of units, e.g., 10000 mg must be expressed as 10 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A).\u003C\u002Fp>\n\n\u003Cp>3. Your Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>,, “Headache &amp; Pain Relief,\" and “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) products are misbranded within the meaning of section 403(s)(2)(C) of the Act [U.S.C. § 343(s)(2)(C)] in that the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1) and 101.36(d)(1). If the whole or entire part is used, this must be declared.\u003C\u002Fp>\n\n\u003Cp>4. Your “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) and “Headache &amp; Pain Relief” products are misbranded within the meaning of section 403(i)(2) of the Act in that the labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h). For example:\u003Cbr>\n• The Blood Pressure Normalizer product label lists “manjishtha”, but this is not the standardized common name of the dietary ingredient. The label must list the standardized common name (SCN) given in the reference Herbs of Commerce, “Indian madder”. The Ayurvedic name for Indian madder (manjishtha) may follow the SCN in parentheses.\u003Cbr>\n• The SCN for the term “Chaksu” must be declared; in the absence of a SCN, the Latin binomial name must be declared.\u003Cbr>\n• The Headache &amp; Pain Relief product declares “dashmoola”. The dietary ingredient(s) that make up the “dashmoola” must be declared by the SCN; in the absence of a SCN, the Latin binomial name for the dietary ingredient must be declared.\u003C\u002Fp>\n\n\u003Cp>5. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(i)(2) [21 U.S.C. § 343(i)(2)] of the Act because the labels fail to declare all ingredients, as required by 21 CFR 101.4. Specifically, the products fail to declare the ingredients of the capsule material.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>We offer the following additional comments:\u003C\u002Fp>\n\n\u003Cp>1. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” product labels do not bear a symbol next to the structure\u002Ffunction claim linking the claim to the disclaimer. Furthermore, the disclaimer fails to be enclosed in a box, in accordance with 21 CFR 101.93(d).\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the U.S. Food and Drug Administration; Attn: Katie Cutajar, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov, or at 300 River Place Suite 5900, Detroit, MI 48207. If you have questions regarding this letter, please contact CO Cutajar at (313) 680-6962 or via email at Kathryn.Cutajar@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast Division 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMaria S. LeMay-Bey, Owner\n\nRecipient Title\n\nIsaiah Orton-Bey, Owner\n\nMoorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\n\n16136 W. 7 Mile Road\n\nDetroit, MI 48235\n\nUnited States\n\nMoorherbs13@gmail.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East VI\n\nUnited States\n\nWARNING LETTER\n\nCMS Case #655674\n\nAugust 1, 2023\n\nDear Isaiah Orton-Bey and Maria LeMay-Bey:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) has conducted an inspection of your manufacturing facility at 16136 W. 7 Mile Road, Livonia, MI 48235-2903 from February 13, 2023 to March 16, 2023. Additionally, FDA reviewed your website at https:\u002F\u002Fmoorherbs.com in May 2023. The inspection and our review of your website revealed serious violations of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) and FDA regulations. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nAt the close of the inspection, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your response to the FDA 483 on April 3, 2023. We address your response below.\n\nUnapproved New Drugs and Misbranded Drugs\n\nFDA reviewed your website, https:\u002F\u002Fmoorherbs.com, in May 2023 and has determined that you take orders there for the products “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Appendix Support,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Cardiovascular System,” “Headache & Pain Relief,” “Healthy Mommy Healthy Baby,” “Quit Smoking,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThyroidism” (also referred to as “HypoThyroid Support”), “Mucus Release,” “Parasite Cleanse,” “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Un-Vax,” “Venereal Defense,” “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”), and “Lungs & Respiratory.” The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\n“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\n\nOn the “Full Body Antibiotic” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Full Body Antibiotic” or “AntiBiotic, Full Body”\n\n• “Our Moor Herbs ‘High Science’ AntiBiotic Formulae targets it all! Use it to help heal respiratory and sinus infections, bronchitis, pneumonia, strep throat, colds, flues [sic], colic, seizures, cough, diabetes, urinary problems, menstrual problems, fever, liver problems, constipation, vaginal discharge, smallpox, enlarged spleen, swelling, asthma, eye cataracts, depression, digestion problems, stomach ulcers, heart trouble, infections, migraine, stroke, pain, . . . as well as urinary tract, kidney, and bladder infections.”\n\n• “Also beneficial for women with yeast infections, trichonomosas, bacterial vaginosis, and chlamydia.”\n\n• “It can be helpful for people with chronic fatigue, HIV, cancer, herpes, and other chronic conditions related with depressed immunity.”\n\n“Anti-Viral”\n\nOn the “Anti-Viral” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Anti-Viral”\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Anti-Viral Formulae is a potent and effective herbal anti-viral conducive for countering all viral conditions.”\n\n“Appendix Support”\n\nOn the “Appendix Support” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs High Science Appendix Support herbal blend is formulated to address the issues that lead to appendicitis: Constipation, Inflammation, and Infection.”\n\n“Blood Pressure” (also referred to as “Blood Pressure Normalizer”)\n\nOn the “Blood Pressure” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Blood Pressure Normalizer”\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Blood Pressure Normalizor [sic] is supported by an Indian medicinal herb belonging to Caesalpiniaceae family of plants.…What makes these seeds really popular, is their ability to lower blood pressure. Acting as a hypotensive agent, this humble seed works wonders for those looking to control their BP naturally.”\n\n• “It is a strong anti bacterial agent...”\n\n“Brain Tune-Up”\n\nOn the “Brain Tune-Up” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “The 2 main ingredients in this blend are Gotu Kola and Ginko Biloba[.] Gotu Kola Leaf… is anti-inflammatory, antiviral, antibacterial, . . . and antifungal. In human studies, gotu kola . . . reduced symptoms of anxiety and depression. It has been used to treat brain-related disorders including mental fatigue, anxiety, depression, memory loss, and insomnia.”\n\n• “Protects the brain from damage”\n\n• “Alleviates stress, anxiety, and depression”\n\n• “Improves memory and mood in Alzheimer’s patients”\n\n• “Ginko Biloba has been repeatedly evaluated for its ability to reduce anxiety, stress and other symptoms associated with Alzheimer’s disease …”\n\n• “Can Help Fight Inflammation.”\n\n• “Reduces Symptoms of Psychiatric Disorders and Dementia.”\n\n• “Can Reduce Anxiety.”\n\n• “Can Treat Depression.”\n\n“Cardiovascular System”\n\nOn the “Cardiovascular System” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “This ‘High Science’ Formula is designed to rebuild a degenerative heart...”\n\n“Headache & Pain Relief”\n\nOn the “Headache & Pain Relief” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Headache & Pain Relief”\n\n• “Our Headache and Pain formula is a natural anodyne concoction that contains plants naturally rich in salicin that naturally breaks down into salicylic acid in the body that is anti-inflammatory in nature and thus effective where there is pain, which is a sensor that something is wrong on a deeper level.”\n\n“Healthy Mommy Healthy Baby”\n\nOn the “Healthy Mommy Healthy Baby” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Note: This blend is also helpful for the following conditions: anemia, low blood, arthritis, asthma, hay fever, sinusitis, gout, emphysema, bronchitis, sinus relief, allergies, high blood pressure, nosebleeds, hemorrhaging, miscarriage (vitamin K), hardened arteries, tooth decay, peptic ulcers, duodenum ulcers, infections, drug and chemical toxins, skin problems, edema, water retention, bowels, gas pains...”\n\n“Quit Smoking”\n\nOn the “Quit Smoking” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Quit Smoking”\n\n• “Our Moor Herbs ‘High Science’ Quit Smoking Formulae is a herbal compound of Nature’s best herbs that have been utilized traditionally to help purify the bloodstream of pollutants and toxins, cleanse the liver…and develop a distaste of insidious addictive man- chemicals.”\n\n“HyperThyroidism” (also referred to as “HyperThyroid Support”)\n\nOn the “HyperThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “HyperThyroidism” or “HyperThyroid Support”\n\n• “For an overactive Thyroid”\n\n• “Moor Herbs High Science HyperThyroidism Relief Formulae is designed for an over-active thyroid gland. Effective for calming down an overactive thyroid and reducing symptoms of hyperthyroidism such as agitation, restlessness, sweating and insomnia.”\n\n“HypoThyroidism” (also referred to as “HypoThyroid Support”)\n\nOn the “HypoThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “HypoThyroidism” or “HypoThyroid Support”\n\n• “For an underactive Thyroid”\n\n• “Moor Herbs High Science Thyroid Support Formula consists of Nature’s plants high in organic iodine and which perform a myriad of beneficial functions for the thyroid gland including…normalizing the function of metabolism. An impaired thyroid gland can lead to a host of negative health problems so good thyroid health is imperative for overall good health.”\n\n“Mucus Release”\n\nOn the “Mucus Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Mucus Release is a powerful ‘High Science’ formula that consists of effective expectorant herbs that help dissolve hardened, stubborn mucus and phlegm that obstruct the mucous membranes and lead to pathology throughout the body…Mucus Release is great for all mucus conditions!”\n\n“Parasite Cleanse”\n\nOn the “Parasite Cleanse” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Parasite Cleanse”\n\n• “Parasite Cleanse ‘High Science’ Formula contain[s] some of Nature’s best anthelmintic herbs that have been traditionally used for centuries by various cultures to remove parasites and worms from the tissues of the body. These creepy critters most certainly rob the body of nutrients and impair critical functions of the organs, glands, and systems of the body.”\n\n“ResErection Extra Strength w\u002F Yohimbe Bark”\n\nOn the “ResErection Extra Strength w\u002F Yohimbe Bark” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs ‘High Science’ Resurrection formulae, is a 100% all-natural herbal-based formula for men experiencing difficulty with attaining and maintaining an erection (penile erectile dysfunction) with the root cause being poor circulation due to poor diet (and lifestyle) – a diet too high in animal protein (meat, flesh, cadavaer, carion, etc.) and animal fat which clogs the veins and arteries and thus impairing circulation which is vital for a healthy, solid, firm, and stiff erection.”\n\n“Tumor Release” (also referred to as “Tumor & Cyst Support”)\n\nOn the “Tumor Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Tumor Release” or “Tumor & Cyst Support”\n\n• “Our Moor Herbs ‘High Science’ Tumor Release Formulae is a safe, sane and effective plant-based anti-neoplastic formulae that is helpful in natural, noninvasive, benign and malignant tumor dissolution.”\n\n• “The formula is useful for all tumor and cyst formations in the body, including uterine and ovarian cysts\u002Ftumors. Good for both internal and external tumors.”\n\n“Un-Vax”\n\nOn the “Un-Vax” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Herbal UN-VAX Formulae is an unique formula designed to remove heavy metal toxins from the body. It is an ideal Formulae to combat mercury (ethyl and methyl) toxicity and aluminum toxicity, both of which are known to cause a plethora of adverse health conditions, especially in children.”\n\n“Venereal Defense”\n\nOn the “Venereal Defense” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Venereal Defense”\n\n• “Our Moor Herbs High Science Venereal Defense Formulae helps foment natural healing of adverse conditions that are passed on from one person to another through intimate contact.”\n\n“Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”)\n\nOn the “Womb Care Cramp Relief & Fibroid Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Womb Care Cramp Relief & Fibroid Release” or “Womb Care: Fibroid and Tumor Release”\n\n• “Our Moor Herbs ‘High Science’ Fibroid\u002FTumor Release Formulae is an all-natural herbal formulation consisting of Nature’s herbs that have an affinity for the female uterus, e.g. Chaste berry and Dong Quai and that are also anti-neoplastic (anti-tumor growth and formation) in nature, e.g. Burdock and Comfrey, thus combating tumorous growth on the uterus, e.g. fibroid tumors or uterine fibroids, facilitating dissolution via the vaginal canal and other eliminative channels.”\n\n• “Fibroids\u002FTumor Release, is a product that can be used in an overall regimen to help females naturally dissolve tumors of the reproductive system and is a great post Womb Cleanse formulae to consume daily.”\n\n• “Recommended for: Uterine fibroids or fibroid tumors, cervical tumors, uterine cysts.”\n\n“Lungs & Respiratory”\n\nOn the “Lungs & Respiratory” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “This High Science Formula is a highly effective anti-tussive and expectorant science formulae.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act [21 U.S.C. 321(p)].\n\nWith certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\nAdulterated Dietary Supplements\n\nThe dietary supplements manufactured at your facility are adulterated under section 402(g)(1) of the FD&C Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111). During the inspection of your facility, FDA investigators observed the following significant violations of the CGMP regulation for dietary supplements:\n\n1. You failed to establish the specifications required under 21 CFR 111.70. Specifically:\n\na. You failed to establish the following required component specifications under 21 CFR 111.70(b) for each component that you use in the manufacture of a dietary supplement: (1) identity specifications, as required by 21 CFR 111.70(b)(1); and (2) component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, when our investigators requested such component specifications for the Coltsfoot, Wild Cherry Bark, and Boneset Herb ingredients used in the manufacturing of your “Lungs & Respiratory” finished dietary supplement product, you were unable to provide such component specifications. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing component specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nb. You failed to establish specifications for dietary supplement labels (labeling specifications), as required by 21 CFR 111.70(d). Specifically, you were unable to provide labeling specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you are in the process of establishing written labeling specifications. We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nc. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you were unable to provide finished product specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing product specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nWe note that once you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, once you have established component specifications and before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c).\n\nYou must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\n\n2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103, and make and keep records of such procedures, as required by 21 CFR 111.140(b)(1). Specifically, you told our investigators that you have no written procedures for quality control operations and that you do not have a quality control program in place.\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of implementing quality control operations to ensure the quality of dietary supplements” and “are also in the process of establishing written procedures and training quality control personnel to ensure all is produced safely, accurately, and according to the standards we have, and are putting, in place.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n3. You did not prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Upon request, you could not provide written MMRs for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products to our investigators. You stated that you did not have these records, and none were provided.\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of establishing Master Manufacturing Records for each dietary supplement and size.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n4. Your batch production record did not include complete information relating to the production and control of each batch, as required under 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, batch production records for “Anti-Viral” manufactured on (b)(4) with lot #(b)(4), “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”) manufactured on (b)(4) with lot #(b)(4), and “Lungs & Respiratory” manufactured on (b)(4) with lot #(b)(4), were collected and reviewed. These records do not include complete information required to be in batch production records. The required information that your records are missing includes, but is not limited to, the following:\n\n• The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)];\n\n• The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)]; The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)];\n\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)];\n\n• The actual results obtained during any monitoring operation [21 CFR 111.260(g)];\n\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\n\n• Documentation at the time of performance of the manufacture of the batch, including [21 CFR 111.260(j)]:\n\no The date on which each step of the MMR was performed [21 CFR 111.260(j)(1)]; and\n\no The initials of the persons performing each step [21 CFR 111.260(j)(2)], including:\n\n The initials of the person responsible for weighing or measuring each component used in the batch;\n\n The initials of the person responsible for verifying the weight or measure of each component used in the batch;\n\n The initials of the person responsible for adding the component to the batch; and\n\n The initials of the person responsible for verifying the addition of components to the batch;\n\n• Documentation at the time of performance of packaging and labeling operations [21 CFR 111.260(k)], including:\n\no The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels [21 CFR 111.260(k)(1)];\n\no An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the MMR [21 CFR 111.260(k)(2)]; and\n\no The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)(3)];\n\n• Documentation at the time of performance that quality control personnel [21 CFR 111.260(l):\n\no Reviewed the batch production record [21 CFR 111.260(l)(1), including:\n\n Review of any monitoring operation required under subpart E of 21 CFR part 111 [21 CFR 111.260(l)(i)]; and\n\n Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements [21 CFR 111.260(l)(ii)];\n\no Approved or rejected any reprocessing or repackaging [21 CFR 111.260(l)(2)]; and\n\no Approved and released, or rejected, the batch for distribution, including any reprocessed batch [21 CFR 111.260(l)(3)]; and\n\no Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement [21 CFR 111.260(l)(4)].\n\n• Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)];\n\n• Documentation at the time of performance of any reprocessing [21 CFR 111.260(n)].\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are still in the process of establishing and implementing the systems (as discussed throughout this document and the investigators observations) that will allow us to produce complete batch records.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n5. You failed to establish and follow written procedures for the requirements to review and investigate a product complaint, as required under 21 CFR 111.553. Specifically, our investigators requested your written procedures to review and investigate a product complaint. You stated that you did not have this procedure, and you did not provide it.\n\nWe have reviewed your April 3, 2023, written response, in which you state, “We’ve been operating since March of 2015 and have never received a complaint. However, we are in the process of establishing written procedures for reviewing and investigating product\u002Fcustomer complaints.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n6. You failed to establish and follow written procedures for when a returned dietary supplement is received, as required under 21 CFR 111.503. Specifically, our investigators requested your written procedures for when a returned dietary supplement is received. You stated that you did not have these written procedures, and none were provided.\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for when a returned dietary supplement is received.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n7. You failed to establish and follow written procedures for holding and distributing operations, as required by 21 CFR 111.453. Specifically, during the inspection, you said you had not established written procedures for holding and distributing operations.\n\nOnce have you established written procedures for your holding and distributing operations, you must make and keep records of such written procedures, as required by 21 CFR 111.475(b)(1).\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for holding and distributing operations.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n8. You did not maintain and clean equipment, utensils, and contact surfaces used to manufacture, package, label, or hold components or dietary supplements, as required under 21 CFR 111.27(d). P\n\nSpecifically, on (b)(4), during the manufacturing of your “Lungs & Respiratory” finished dietary supplement product, your multi-functional grinder was observed with a light green and brown residue inside the bowl and the (b)(4) plastic capsule filling equipment was observed with a light brown powder and brown staining. Furthermore, the method you used for cleaning and sanitizing your utensils and equipment does not align with, and directly contradicts, the manufacturer’s written instructions on the cleaning and sanitizing products. Additionally, you do not have any written procedures for cleaning or sanitizing your utensils and equipment, as required under 21 CFR 111.25(c).\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “have since corrected the way we wash and sanitize our utensils and equipment, according to the instructions indicated on the cleaning agents we use, combined with regulations outlined under Michigan Food Law.” These corrections will be evaluated during the next FDA inspection of your firm. You also stated in your response that you “are in the process of establishing written procedures for cleaning and sanitizing utensils and equipment.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nMisbranded Dietary Supplements\n\nIn addition, your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”),, “Headache & Pain Relief,” and “Bright Eyes” products are misbranded dietary supplements under Section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101 as follows:\n\n1. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the labels is are incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Lungs and Respiratory, Full Body Antibiotic, Antiviral, Blood Pressure Normalizer, Headache & Pain Relief, and Bright Eyes product labels’ serving sizes is declared as “3 Capsules or 3 Scoops” and are not specific to each product.\n\n2. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of sections 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling of the products does not comply with 21 CFR 101.36. Specifically,\n\n• The title “Supplement Facts” is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\n\n• The dietary ingredients are not indented under the title “Proprietary Herbal Blend”, in accordance with 21 CFR 101.36(c)(2).\n\n• The quantitative amount by weight per serving of proprietary blend does not use metric measures in appropriate units (i.e., 1000 units must be declared in the next higher set of units, e.g., 10000 mg must be expressed as 10 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A).\n\n3. Your Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”),, “Headache & Pain Relief,\" and “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) products are misbranded within the meaning of section 403(s)(2)(C) of the Act [U.S.C. § 343(s)(2)(C)] in that the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1) and 101.36(d)(1). If the whole or entire part is used, this must be declared.\n\n4. Your “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) and “Headache & Pain Relief” products are misbranded within the meaning of section 403(i)(2) of the Act in that the labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h). For example:\n\n• The Blood Pressure Normalizer product label lists “manjishtha”, but this is not the standardized common name of the dietary ingredient. The label must list the standardized common name (SCN) given in the reference Herbs of Commerce, “Indian madder”. The Ayurvedic name for Indian madder (manjishtha) may follow the SCN in parentheses.\n\n• The SCN for the term “Chaksu” must be declared; in the absence of a SCN, the Latin binomial name must be declared.\n\n• The Headache & Pain Relief product declares “dashmoola”. The dietary ingredient(s) that make up the “dashmoola” must be declared by the SCN; in the absence of a SCN, the Latin binomial name for the dietary ingredient must be declared.\n\n5. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(i)(2) [21 U.S.C. § 343(i)(2)] of the Act because the labels fail to declare all ingredients, as required by 21 CFR 101.4. Specifically, the products fail to declare the ingredients of the capsule material.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nWe offer the following additional comments:\n\n1. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” product labels do not bear a symbol next to the structure\u002Ffunction claim linking the claim to the disclaimer. Furthermore, the disclaimer fails to be enclosed in a box, in accordance with 21 CFR 101.93(d).\n\nYour response should be sent to the U.S. Food and Drug Administration; Attn: Katie Cutajar, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov, or at 300 River Place Suite 5900, Detroit, MI 48207. If you have questions regarding this letter, please contact CO Cutajar at (313) 680-6962 or via email at Kathryn.Cutajar@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast Division 6","Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.","moorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national","2026-10-26T08:09:27.900006+00:00","2023-09-19","Division of Human and Animal Food Operations East VI","Maria S. LeMay-Bey, Owner","2026-08-20T00:39:30.007+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2023-08-01",5,{"510k":120,"classification":121,"enforcement":122,"event":123,"event_backfill":124,"pma":125,"warning_letter":126},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]